The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Szeto, Cheuk Chun ^a   Kwan, Bonnie Ching Ha ^a   Chow, Kai Ming ^a   Leung, Chi Bon ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; POTASSIUM;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION; HUMAN; HYPERKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; FEMALE; FUMARATES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; PROTEINURIA; RENIN; TREATMENT OUTCOME;

EID: 84877626276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062736     Document Type: Article

References (33)

1. D'Amico G, (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 245: 709-727.
2. Li PKT, Ho KKL, Szeto CC, Yu LM, Lai FM, (2002) Prognostic Indicators of IgA Nephropathy in the Chinese - Clinical and Pathological Perspectives. Nephrol Dial Transplant 17: 64-69.
3. Haas M, (1997) Histologic subclassification of IgA nephropathy: a clinico-pathologic study of 244 cases. Am J Kidney Dis 29: 829-842.
4. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, et al. (1994) ACE inhibition reduce proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9: 265-269.
5. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, et al. (1999) Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856.
6. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, et al. (1998) The antiproteinuria effect of angiotensin antagonsim in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9: 2308-2317.
7. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, et al. (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751-760.
8. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G, (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35: 1155-1165.
9. Staessen JA, Li Y, Richart T, (2006) Oral renin inhibitors. Lancet 368: 1449-1456.
10. Fisher NDL, Hollenberg NK, (2005) Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 16: 592-599.
11. Stanton A, Jensen C, Nussberger J, O'Brien E, (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42: 1137-1143.
12. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, et al. (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111: 1012-1018.
13. van Paassen P, de Zeeuw D, Navis G, de Jong PE, (2000) Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 15: 637-643.
14. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, et al. (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73: 1419-1925.
15. To KF, Choi PC, Szeto CC, Li PK, Tang NL, et al. (2000) Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis 35: 392-400.
16. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545.
17. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556.
18. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, et al. (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17: 2937-2944.
19. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, et al. (2003) Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92: 406-410.
20. Tang SC, Lin M, Tam S, Au WS, Ma MK, et al. (2012) Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant 27: 613-618.
21. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.
22. Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY, et al. (2012) Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol 13: 89.
23. Leung WY, So WY, Tong PC, Lo MK, Lee KF, et al. (2004) The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 19: 2519-2525.
24. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, et al. (2011) Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 6: 1025-1031.
25. Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, et al. (2012) Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease. Am J Hypertens 25: 636-639.
26. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, et al. (2010) Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 33: 2304-2309.
27. Moist L, (2012) Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone. Ann Intern Med 156: JC6-9.
28. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, et al. (2011) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 13: 107-114.
29. Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Böhm M, et al. (2011) Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 13: 100-106.
30. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al. (2012) Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 13: 387-393.
31. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P, (2012) Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opin Drug Saf 11: 659-670.
32. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al. (2012) Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med 367: 2204-2213.
33. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.